secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001171843-22-007233
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q3 revenue $40.3M (+2% YoY); net loss ($4.2M); Cingal Phase III hits endpoint
--------------------------------------------------------------------------------

- Revenue $40.3M (+2% YoY); OA Pain Mgmt $25.7M (-2%), Joint Preservation $11.8M (+6%), Non-Ortho $2.8M (+27%).
- Net loss ($4.2M) vs net income $0.6M prior year; adjusted net loss ($0.7M); adjusted EBITDA $4.1M vs $5.7M.
- Cingal Phase III (Cingal 19-01) achieved primary endpoint — superiority over steroid alone at 26 weeks; FDA meeting planned.
- Hyalofast pivotal Phase III 96% enrolled (193 patients); full enrollment expected early 2023; PMA filing on track for 2025.
- FY2022 guidance: overall revenue toward upper end of low to mid single-digit growth; OA Pain Mgmt now expected up mid to upper single-digit %.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184322007233/0001171843-22-007233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184322007233/f8k_110822.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-007233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer